苑東生物(688513.SH):3項藥品擬中標第五批國家組織藥品集採
格隆匯6月23日丨苑東生物(688513.SH)公吿,2021年6月23日,公司參加了聯合採購辦公室組織的第五批全國藥品集中採購的投標工作。公司的格隆溴銨注射液、達比加羣酯膠囊和鹽酸法舒地爾注射液擬中選本次集中採購。
據悉,2020年格隆溴銨注射液的銷售收入達到10.45萬元,2020年鹽酸法舒地爾注射液的銷售收入達到738.49萬元。
本次集中採購是國家組織的第五批藥品集中帶量採購,採購週期中,醫療機構將優先使用本次藥品集中採購中選藥品,並確保完成約定採購量。本次公司擬中選價格與原中標價格相比有一定程度下降。
若公司後續簽訂採購合同並實施後,將有利於進一步擴大相關產品的銷售,提高市場佔有率,促進公司相關產品國內市場的開拓,提升公司的品牌影響力,對公司的未來經營業績產生積極的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.